Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings
CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–#birthcontrol–Contraline, Inc., a clinical-stage medical device company announced the acceptance of abstracts detailing the initial results from the company’s first in human clinical trial of ADAM, a hydrogel-based, long-lasting, non-hormonal, and non-permanent male contraceptive. The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two … [Read more…]
